Scilex Pharmaceuticals, a subsidiary of Scilex Holding Company, has announced a successful end-of-Phase II meeting with the FDA for SP-103 (lidocaine topical system) 5.4%, a next-generation, triple-strength formulation of ZTlido, for the treatment of chronic neck pain associated with muscle spasms. The FDA has provided a clear path forward to a New Drug Application (NDA) upon completion of Phase III trials. This development marks a significant step for Scilex in addressing the U.S. low back and neck pain market, which is projected to reach $134.5 billion.
SP-103: A Promising Non-Opioid Solution
SP-103 is designed as a triple-strength formulation of lidocaine, aiming to provide enhanced pain relief compared to existing topical treatments. According to market research by Syneos Health Consulting, SP-103 has the potential to achieve peak sales of $1.2 billion annually within six years of its launch. This projection underscores the significant unmet need for effective non-opioid pain management solutions.
"We are very pleased with the end of Phase II meeting and received a clear path forward to NDA for our blockbuster product candidate, SP-103," said Dmitri Lissin, M.D., Chief Medical Officer of Scilex. "SP-103 has the potential to meet our core goal of developing leading pain management therapies to significantly improve the lives of patients for the treatment of chronic neck pain associated with muscle spasms who are seeking new effective treatments."
Addressing Chronic Neck Pain
Chronic neck pain is a prevalent condition affecting a significant portion of the adult population. SP-103 targets this condition with a high-concentration lidocaine topical system, potentially offering improved therapeutic responses. The company believes its technology allows for a much higher lidocaine concentration than other topical lidocaine systems, which is crucial for achieving the desired therapeutic effect.
Scilex's Existing Portfolio and Future Plans
Scilex currently markets three FDA-approved products: ZTlido (lidocaine topical system) 1.8% for postherpetic neuralgia, ELYXYB, an oral solution for acute migraine, and Gloperba, a liquid oral version of colchicine for gout flare prophylaxis. ZTlido has shown an average growth of 50% in gross sales over the past two years, demonstrating the market demand for innovative pain management solutions. The company is also exploring strategic options to maximize shareholder value, including a potential spinoff or public listing of Scilex Pharmaceuticals Inc.
Market Opportunity
The U.S. market for low back and neck pain is substantial, estimated at $134.5 billion. Scilex's focus on non-opioid pain management aligns with the growing need for alternatives to opioid-based treatments. With a clear path to Phase III trials for SP-103 and a strong existing portfolio, Scilex is well-positioned to address this market need.
